Examples of successful targeted therapies in cancer include, among many others, the small molecule inhibitors of the BRAF V600 oncogene in melanoma, and monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) in non-small cell lung cancer (NSCLC) [1]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.